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Abstract
Study Objectives: Insomnia is a leading cause of disability in postmenopausal women. Multicomponent cognitive-behavioral therapy for insomnia (CBTI) is a firstline treatment for chronic insomnia, but support for its efficacy in treating menopause-related insomnia is scarce. The present study evaluated whether CBTI is an
efficacious treatment for menopause-related chronic insomnia, and whether sleep restriction therapy (SRT)—a single component of CBTI—is equally efficacious
compared with CBTI.
Methods: In a single-site, randomized controlled trial, 150 postmenopausal women (56.44 ± 5.64 years) with chronic DSM-5 insomnia disorder related to menopause
were randomized to three treatment conditions: sleep hygiene education (SHE), SRT, or CBTI. Blinded assessments were performed at baseline, posttreatment, and
6 months after treatment. The Insomnia Severity Index (ISI) and sleep diaries served as primary outcomes.
Results: From baseline to posttreatment, ISI decreased 7.70 points in the CBTI group (p < .001), 6.56 points in the SRT group (p < .001), and 1.12 in the SHE group
(p = .01). Although average sleep duration increased in all groups by 6 month follow-up, CBTI patients obtained 40–43 more minutes of nightly sleep than those
who received SHE or SRT. Remission rates in the CBTI (54%–84%) and SRT (38%–57%) groups were higher than SHE patients (4%–33%) at posttreatment and 6 month
follow-up. CBTI patients were generally more likely to remit than SRT patients.
Conclusions: CBTI and SRT effectively treat menopause-related insomnia disorder and are superior to SHE. Response to CBTI and SRT is similar, but CBTI
outperforms SRT in improving sleep maintenance, which may increase likelihood of remission.
Clinical Trial Name: Behavioral Treatment of Menopausal Insomnia: Sleep and Daytime Outcomes. URL: clinicaltrials.gov. Registration: NCT01933295.

Statement of Significance
Sleep problems like insomnia are a chief complaint among women during and after the menopause transition. Hormone replacement
therapy, hypnotics, and psychotropic medications have long been the only offered interventions for menopause-related insomnia. However,
these medications have poor support as standalone treatments for menopausal insomnia and many carry risks for serious side effects.
Recent evidence suggests that cognitive-behavioral interventions may alleviate insomnia symptoms associated with menopause. In this
clinical trial, we showed that cognitive-behavioral therapy for insomnia (CBTI) and sleep restriction therapy (SRT) are superior treatments
for menopause-related insomnia when compared with sleep hygiene education. Moreover, results of this study suggest that CBTI may
produce higher likelihood of remission and more durable results than SRT for some women with menopausal insomnia.
Key words: insomnia; CBTI; sleep hygiene; menopause; sleep restriction
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Introduction

Methods
Participants and procedure
This study was conducted in a large 6-hospital health system
in the state of Michigan. Participants were recruited from the
health system in primary care and the sleep clinic, as well as
from the community via newspaper advertisements and from
a database of prior sleep center studies. To be eligible, women
must have been postmenopausal (12 consecutive months
without menses), reported wake after sleep onset (WASO;
wakefulness in the middle of the night after falling asleep) of
an hour or more on ≥3 nights per week, and met criteria for
DSM-5 insomnia disorder that onset or was exacerbated during
the perimenopausal or postmenopausal period per clinical
interview with a registered nurse with specialty training in
behavioral sleep medicine. Regarding our operationalization
of menopause-related insomnia, participants had to endorse
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Insomnia is endemic to women transitioning through
menopause [1–3]. In the United States, the highest rates
of menopause-related insomnia complaints are among
postmenopausal women at 43%–48% [1]. Menopause itself—via
hormonal changes and related symptoms—often leads to sleep
deterioration, thereby triggering the onset of insomnia disorder
[2, 4]. As menopausal women with disturbed sleep endorse more
comorbid chronic illnesses, greater alcohol consumption, higher
stress, more depression, and overall worse health than good
sleeping menopausal women [5, 6], it is imperative to provide
efficacious treatments for menopause-related insomnia.
Despite being one of the most common menopause-related
complaints, treatment options for menopausal insomnia have
been rather limited. Most treatment options to improve sleep
in menopause involve pharmacotherapy, but have produced
mixed or weak results [3]. Despite hormonal imbalance having
a suspected etiological role in menopausal insomnia, support
for hormone replacement therapy (HRT) as an efficacious
standalone insomnia treatment is scarce as results are often
nonsignificant or, at best, statistically significant but clinically
underwhelming [3, 7, 8]. As HRT has limited efficacy and carries
serious health risks [9, 10], other forms of pharmacotherapy
have been tested. Randomized controlled trials (RCTs) support
the immediate efficacy of zolpidem [11], ramelteon [12], and
eszopiclone [13] for menopausal insomnia, but data on longterm hypnotic use and treatment durability in this population
have gone unreported. Furthermore, recent recommendations
advise against hypnotics in this population due to the risks
associated with long-term hypnotic use, particularly among
older adults [3]. Other medications, including antidepressants,
have demonstrated mixed benefits for sleep in menopause,
but little evidence supports these as standalone treatments for
insomnia disorder in this population [3].
Until recently, cognitive-behavioral interventions for
menopause-related insomnia had not been investigated.
Cognitive-behavioral therapy for insomnia (CBTI) is the most
commonly
administered
nonpharmacological
insomnia
treatment among sleep specialists. Importantly, this is not true
for nonspecialists who are more likely to deliver sleep hygiene
education (SHE) as a standalone insomnia treatment. CBTI is a
multicomponent treatment comprised of behavioral, cognitive,
and educational components believed to target critical factors
that maintain insomnia over time. As a first-line treatment for
insomnia disorder [14], CBTI is equally effective as hypnotics
for treating insomnia in the short-term, and more effective and
better tolerated than hypnotics in the long-term [15]. Thus, it is
surprising that CBTI for menopausal insomnia has only recently
been investigated. As one of the MsFlash trials, perimenopausal
and postmenopausal women with self-reported insomnia
symptoms were randomized to telephone delivery of CBTI or
menopause education control [16]. Follow-up data immediately
after treatment then 16 weeks later showed substantial and
durable reductions in insomnia symptoms in the CBTI group, but
not the control condition. Despite these initial positive results,
many gaps exist in our knowledge of cognitive and behavioral
interventions for menopausal insomnia.
First, to firmly establish the efficacy of CBTI for menopauserelated insomnia, it is imperative to examine only women
whose insomnia onset or exacerbation coincides with the

menopause transition. That is, as etiological factors likely differ
between insomnia disorders that onset prior to the menopause
transition vs onsets during or after menopause, investigating
insomnia cases specifically associated with menopause
transition will offer the clearest picture of treatment effects on
actual menopause-related insomnia. Equally important is that
patients should be diagnosed by a sleep specialist per current
ICSD-3 [17] or DSM-5 [18] insomnia disorder criteria to ensure
the validity of treatment effects. Second, although evidence
suggests CBTI to be superior to menopause education in the
treatment of menopausal insomnia, it remains unclear how
CBTI compares with insomnia-focused interventions. CBTI
treatment effects should be demonstrated as superior to realworld clinical practices, which often involve administering SHE
as a standalone nonpharmacological treatment as usual. Thirdly,
CBTI is just one treatment option for insomniacs preferring
nonpharmacological intervention. Other nonpharmacological
insomnia treatments have strong support for the treatment of
insomnia, but have not been examined in menopause-related
insomnia. Sleep restriction therapy (SRT) is an empirically
supported standalone insomnia treatment [19]. Notably, sleep
restriction is a primary component of CBTI. And as a standalone
treatment, SRT often involves fewer sessions than CBTI, which
can improve access to care by producing less patient burden.
The present study was a single-site RCT comparing CBTI,
SRT, and SHE for the treatment of menopause-related DSM-5
insomnia disorder in a sample of 150 postmenopausal women
[1]. We hypothesized that patients receiving CBTI or SRT would
report greater improvements in insomnia symptoms and
higher rates of remission immediately after treatment and at
6 month follow-up when compared with patients receiving SHE.
In addition, we anticipated that the additional components
of CBTI (i.e. stimulus control, cognitive therapy, progressive
muscle relaxation, and sleep hygiene) would have substantial
incremental value to treatment and reinforce longer-term
adaptive sleep behaviors when compared with SRT. Therefore,
we hypothesized that immediate posttreatment effects would
be similar between the CBTI and SRT groups, but that CBTI
would produce more durable treatment effects over the longer
term as evidenced by substantially better sleep and higher
remission rates for CBTI treatment compared with SRT at
6 month follow-up.
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SRT (N = 52), and (3) CBTI (N = 52). Randomization was conducted
using 150 allocations (50 per group) that were ordered randomly
and concealed in envelopes. Group allocation for each participant
was then assigned using the order of concealed envelopes. Two
participants in both the SRT and CBTI conditions were disqualified
during treatment for changes in medication or new onset comorbid
sleep disorder. These two allocations were replaced in random
order by a research staff member not involved with this study,
and recruitment included two more individuals to replace those
who were disqualified. This resulted in 50 participants completing
treatment in each of the three conditions. Although doubleblind could not be achieved given the nature of the behavioral
interventions, participants were not informed which treatments
were considered control versus active, or of the specific hypotheses.
Assessments of insomnia symptoms and sleep parameters were
collected prior to treatment, at posttreatment (within 2 weeks of
completing treatment), and 6 months after treatment completion.
All 150 participants provided posttreatment outcome data,
whereas 16% of treatment completers did not provide follow-up
data 6 months later (Figure 1).
Cognitive-behavioral therapy for insomnia
Women randomized to CBTI completed six face-to-face sleep
therapy sessions with a registered nurse who specializes in
behavioral sleep medicine. CBTI is a structured, multimodal
treatment that targets sleep-disruptive behaviors and beliefs
(see Perlis et al. [20]). Data from clinical trials consistently
show that CBTI is as efficacious as pharmacological treatment
in the short-term, but produces superior treatment response
in the long-term [14, 15]. CBTI patients received 6 weekly
sessions, which covered behavioral (sleep restriction and
stimulus control) and cognitive (e.g. cognitive restructuring)
components, as well as relaxation strategies (e.g. progressive
muscle relaxation and autogenic training) and sleep hygiene.
Because CBTI was a 6 week intervention, posttreatment
outcomes were measured 6 weeks after pretreatment baseline.
Fidelity monitoring for the nurse therapist included weekly
supervision meetings with one of the two licensed PhD clinical
psychologists, both of whom are certified in behavioral sleep
medicine. Supervision meetings included discussions of cases,
problem-solving, and listening to and providing feedback
based on recorded therapy sessions.

Figure 1. Flow chart of study enrollment and participation.

Sleep restriction therapy
SRT is an effective standalone behavioral treatment for insomnia
[19]. Although SRT actually predates CBTI, SRT is now commonly
packaged as part of CBTI and is typically considered one of CBTI’s
main active ingredients. As CBTI consists of SRT plus multiple
other components, SRT is the briefer of the two interventions.
Here, SRT was delivered as a 2 week intervention. Specifically, the
initial face-to-face session consisted of reviewing patient sleep
history, education and rationale for sleep restriction practices,
and behavioral homework with a registered nurse who specializes
in behavioral sleep medicine. Then four follow-up sessions (three
phone contacts, each 3–4 days apart, followed by a second faceto-face session) were delivered across the following 2 weeks and
were used to titrate sleep schedules based on sleep diary data.
Because SRT was a 2 week intervention, posttreatment outcomes
were measured 2 weeks after pretreatment baseline. Fidelity
monitoring for the SRT condition was the same as described in
the CBTI section above.
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that current insomnia onset or worsened within ±6 months
of menopause onset to be eligible. In addition, objective sleep
disturbance had to be evident per mean WASO of ≥45 min across
two overnight polysomnography (PSG) studies (adaptation night
+ baseline night, and neither night could have WASO of <30 min).
Exclusionary criteria also included prior or current DSM-5 major
depression per diagnostic interview, sleep–wake disorders other
than insomnia [examined on PSG adaptation night (obstructive
sleep apnea defined as apnea–hypopnea index of ≥15, periodic
limb movements defined as arousal frequency of ≥15) and per
patient report], and medications influencing sleep (prescription
and nonprescription sleep aids, herbal supplements, and any
antidepressants taken at night), although women receiving
hormone therapy were permitted to participate.
Refer to Figure 1 flow chart of study enrollment and
participation. A total of 317 postmenopausal women were
screened for eligibility. Of these individuals, 107 women were
ineligible and another 56 declined to participate or had scheduling
conflicts. Thus, 154 postmenopausal women were randomized to
1 of 3 treatment conditions: (1) SHE treatment as usual (N = 50), (2)

3
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Measures
All self-report measures were collected with online surveys
hosted by Qualtrics, LLC, and study personnel were blinded
to these data. Insomnia symptoms and sleep parameters
were collected using the Insomnia Severity Index (ISI) and
the consensus sleep diary [22]. The ISI is a 7-item self-report
measure of insomnia symptom severity [23]. A cutoff of ISI
≥ 11 indicates clinically significant self-reported insomnia
severity in RCTs, whereas a cutoff of ISI ≤ 7 indicates remission
[24]. The Ford Insomnia Response to Stress Test (FIRST) [25]
measures trait-like stress-related sleep reactivity (i.e. tendency
to experience sleep disturbance in response to stress) and was
administered to characterize pretreatment sleep reactivity in
this sample. Sleep diary data were collected for 2 weeks before
treatment (pretreatment), the first 2 weeks after completing
treatment (posttreatment), and for a final 2 weeks at 6 months
after treatment (6 month follow-up). Diary data included
sleep onset latency (SOL; in minutes), frequency of nighttime
awakenings (number of awakenings), WASO (in minutes), sleep
quality (SQ; 1–5 scale, higher scores indicating better quality),
time in bed (TIB; time between bedtime and wake time), total
sleep time (TST; TIB minus SOL and WASO and period between
bedtime and lights out), and sleep efficiency (SE%; ratio of TST
to TIB, with higher percentages indicating more TIB spent asleep
with SE < 85% indicating inefficient sleep).

Analysis plan
Analyses were conducted using SPSS version 25. Overall
demographics and pretreatment characteristics were first
presented and cross-sectionally compared across the three
treatment conditions to identify group differences before
treatment. To test treatment effects, we first ran 3 × 2 repeated
measures ANOVAs to examine Treatment × Time interactions
for changes in sleep parameters (ISI and diary reports)
from pretreatment to immediate posttreatment. With 150
participants across three groups (n = 50 in each), power analysis
revealed over 90% power to detect medium-sized interactions.
For diary data, we excluded statistical outliers on SOL (>120) and
analyzed data from participants with full diary data at all three
time points, resulting in analyzing diary data in 137 women.
After testing for Treatment × Time interaction effects, paired
samples t-tests were conducted within each condition to test

for potential simple effects; significant results (p < .05) were then
followed-up with Cohen’s d estimation of effect size specifically
designed for paired samples t-tests, which accounts for the
correlation between the pretreatment and posttreatment values
[26]. In addition, a cross-sectional one-way ANOVA was used to
compare mean levels for each treatment outcome to determine
differences in symptom levels across groups. These analyses
were then repeated to compare 6 month follow-up data with
pretreatment symptomatology. Lastly, we compared remission
rates across treatment conditions at posttreatment and 6 month
follow-up based on ISI and diary-based quantitative criteria.
Importantly, recent evidence suggests that remission based on
global insomnia complaints may misrepresent individuals who
continue to experience sleep disturbance; thus, incorporation of
self-reported quantitative criteria into remission status has been
strongly urged [27]. Thus, we examined insomnia remission per
three different operationalizations: (1) ISI ≤ 7, (2) SE% ≥ 85%, and
(3) SOL and WASO ≤ 30 min each. We evaluated remission rates
by treatment for all three remission operationalizations.

Results
Screening and sample characteristics
See Table 1 for sample characteristics and symptom levels for
the full sample and each of the treatment groups. Our sample
was largely comprised of non-Hispanic White (52.0%) and nonHispanic Black women (39.3%). The mean number of years
since last menstrual period was 7.12 ± 7.04 years. Only four
patients reported current HRT (2.7%), and 23.3% of the sample
reported medical menopause due to hysterectomy (partial
or complete), chemotherapy, or endometrial ablation. Sleep
reactivity was high in the sample (FIRST: 21.86 ± 6.05), indicating
that postmenopausal insomniacs have highly stress-reactive
sleep systems. Prior to treatment, mean ISI scores were in the
clinical range (ISI: 15.17 ± 3.98). Per sleep diaries, WASO ratings
were in the clinical range for 75.2% of the sample (WASO >
30 min [28]), compared with just 42.3% of the sample struggling
to fall asleep (sleep latency > 30 min [28]). Duration of sleep
was short (TST: 5 hr 43 m ± 86 m) and mean SE% was < 85%,
thereby indicating inefficient sleep (71% ±15%). Mean SQ ratings
showed that participants largely reported having “fair” sleep
at night. Comparisons of sociodemographic characteristics
and pretreatment presentation revealed no differences
across the three conditions. Participants who dropped out at
6 month follow-up did not differ from study completers on any
pretreatment or posttreatment outcomes.

Treatment effects on insomnia symptoms and sleep
diary parameters
Refer to Table 2 for full results on posttreatment outcomes.
Insomnia symptoms
We first evaluated changes in our primary outcome measure:
insomnia symptom severity (Figure 2). A repeated measures
ANOVA evaluating changes in ISI scores from pretreatment
to posttreatment showed a significant Treatment × Time
interaction. Even so, follow-up paired samples t-tests showed
that all three treatment groups reported reductions in ISI scores.
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Sleep hygiene education (SHE), i.e., minimal intervention control
condition
Women randomized to the online SHE condition received 6
weekly emails including general, nonpersonalized information
on the following topics: the basics of endogenous sleep
regulation; the impact of sleep on health problems such as
obesity, diabetes, and hypertension; the effects of stimulants
and other sleep-disruptive substances; the relationship between
sleep, diet, and exercise; and tips on creating a sleep-conducive
bedroom environment. Sleep hygiene is neither the primary
cause nor a sufficient therapeutic target in insomnia disorder
and therefore served as an ideal minimal intervention control
condition and real-world comparator [21]. Because SHE was a 6
week intervention, posttreatment outcomes were measured 6
weeks after pretreatment baseline.
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Table 1. Sample characteristics prior to treatment (n = 150)
All participants

SHE

SRT

CBTI

Sample size

150

50

50

50

Age

56.44 ± 5.64 years

57.24 ± 5.55 years

56.76 ± 5.39 years

55.32 ± 5.90 years

78; 52.0%
59; 39.3%
1; 0.7%
1; 0.7%
2; 1.3%
9; 6.0%
4; 2.7%

26; 52.0%
20; 40.0%
–
–
1; 2.0%
3; 6.0%
3; 6.0%

28; 56.0%
17; 34.0%
1; 2.0%
1; 2.0%
–
3; 6.0%
1; 2.0%

24; 48.0%
22; 44.0%
–
–
1; 2.0%
3; 6.0%
0; 0.0%

35; 23.3%
7.12 ± 7.04

9; 18.0%
7.33 ± 7.79

12; 24.0%
6.93 ± 6.79

14; 28.0%
7.09 ± 6.65

F(2,147) = 0.04, p = .96

21.86 ± 6.05; 73.8%

22.73 ± 6.53; 75.0%

21.08 ± 4.95; 75.5%

21.79 ± 6.58; 70.8%

F(2,147) = 0.90, p=.41

15.17 ± 3.98; 88.7%
5 hr 46 m ± 77 m
2.96 ± .54; Fair
30.83 ± 18.15; 42.3%
2.75 ± 1.24
57.72 ± 36.27; 75.2%
71% ± 15%

15.36 ± 4.36; 86.0%
5 hr 47 m ± 77 m
3.01 ± .50; Fair
28.37 ± 12.40; 34.1%
2.93 ± 1.35
61.83 ± 39.50; 79.5%
72% ± 14%

15.20 ± 3.67; 88.0%
5 hr 27 m ± 74 m
2.87 ± .54; Fair
34.86 ± 23.82; 46.8%
2.59 ± .99
62.33 ± 37.02; 78.7%
69% ± 14%

14.94 ± 3.97; 92.0%
6 hr 5 m ± 77 m
3.02 ± .57; Fair
29.06 ± 15.60; 45.7%
2.73 ± 1.35
49.07 ± 31.14; 67.4%
75% ± 13%

F(2,147) = 0.14, p = .87
F(2,132) = 2.94, p = .06
F(2,134) = 1.14, p = .32
F(2,134) = 1.80, p = .17
F(2,134) = 0.91, p = .40
F(2,134) = 2.00, p = .14
F(2,132) = 2.79, p = .07

FIRST = ford insomnia response to stress test. Medical menopause = menopause due to medical treatments including complete or partial hysterectomy,
chemotherapy, or endometrial ablation.
ISI % is proportion that is ISI ≥ 11. All other sleep parameters collected using the consensus sleep diary. One-way ANOVAs used to compare pretreatment means, with
Bonferroni post hoc comparisons.

However, large insomnia reductions were observed in the SRT
(MeanT2−T1: −6.56, d = 1.66) and CBTI (MeanT2−T1: −7.70, d = 1.43)
groups, whereas the SHE group experienced only a modest
reduction of 1.12 points (d = .37). One-way ANOVA with post hoc
Bonferroni comparisons showed that ISI scores were lower at
posttreatment in the SRT and CBTI groups compared with the
SHE group, but that the SRT and CBTI groups did not differ.
Six months later, reductions in ISI from baseline were large
in the SRT (MeanT3−T1: −7.02, d = 1.62) and CBTI (MeanT3−T1: −8.03,
d = 1.38) groups, but moderate in the SHE group (MeanT3−T1: −2.22,
d = .57). Comparing groups, ISI scores remained lower in SRT
and CBTI patients than SHE patients, although ISI scores did not
differ between SRT and CBTI groups (Table 2).
Total sleep time
Despite large acute improvements in insomnia symptom severity
in two of the three groups, TST at posttreatment only increased
in the SRT group, although modestly (d = .35). However, as there
was a trend for pretreatment TST to be higher for CBTI women
than for SRT women, this observed increase in TST for the SRT
group could be regression to the mean, especially considering
that SRT actively limits time spent in bed. Importantly, the three
groups did not differ on TST at posttreatment (Table 2). When
examining changes in TST at 6 month follow-up, paired samples
t-tests showed that TST increased moderately in all groups from
pretreatment baseline (SHE MeanT3−T1: +26 min; SRT MeanT3−T1:
+43 min; CBTI MeanT3−T1: +48), yet TST was 40–43 min longer in
the CBTI group than in the SRT and SHE groups. TST did not
differ between SRT and SHE groups.

Sleep quality
Self-reported SQ followed a similar pattern as ISI scores (Table 2;
Figure 2). A significant Treatment × Time interaction was observed,
and paired samples t-tests showed large increases in SQ in SRT
(d = 1.04) and CBTI (d = .91) patients, but no improvement in
the SHE group (p = .18). Accordingly, posttreatment SQ was rated
more positively in the SRT and CBTI groups than the SHE group,
although the SRT and CBTI did not differ from one another.
Six months later, SQ was higher in the SRT and CBTI groups
than in the SHE group (Table 2). Paired samples t-tests revealed
large increases in SQ for the SRT (d = 1.09) and CBTI (d = 1.31)
groups, but no improvement in the SHE group (MeanT3−T1: p = .14).
Sleep onset latency
SRT and CBTI patients reported reduced SOL at posttreatment
(Table 2; Figure 2). A Treatment × Time interaction was significant
such that large decreases in SOL were observed in the SRT
(MeanT2−T1: −16.51 min, d = 1.14) and CBTI (MeanT2−T1: −12.94 min,
d = .95) groups, whereas no significant change was observed
in the SHE group (MeanT2−T1: −3.06 min, p = .24). Concordantly,
posttreatment sleep latency was shorter in the SRT and CBTI
groups than the SHE group, whereas the SRT and CBTI groups
did not differ on sleep latency.
We also observed large reductions in SOL at 6 months after
treatment in the SRT (MeanT3−T1: −14.02 min, d = .90) and CBTI
(MeanT3−T1: −10.45 min, d = .83) groups, along with moderate
reductions in latency to sleep in the SHE group (MeanT2−T1: −6.72,
d = .52). However, the three treatment groups no longer differed
on SOL at 6 month follow-up.
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Race
White
Black
Hispanic or Latinx
Multiracial
Other
Did not answer
Hormone replacement
therapy
Medical menopause
Years since last
menstruation
FIRST
Pretreatment
ISI
Total sleep time
Sleep quality
Sleep latency
Nighttime awakenings
Wake after sleep onset
Sleep efficiency

F (2,147) = 1.58,
p = .21
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Table 2. Comparing CBTI vs SRT vs SHE on sleep parameters and nocturnal insomnia symptoms
Δ Pre- to posttreatment

6 month Follow-up

Δ Pre- to 6 month follow-up

F(2,147) = 37.33, p < .001
14.24 ± 4.49*,†; 78.0%
8.64 ± 4.18‡; 34.0%
7.24 ±4.18‡; 22.0%
F(2,134) = 0.96, p = .39
6 hr 1 m ± 66 m
5 hr 53 m ± 74 m
6 hr 13 m ± 78 m
F(2,134) = 7.53, p = .001
3.12 ± .64*,†; Fair
3.53±.63‡; Fair/Good
3.63 ± .66‡; Good
F(2,134) = 5.73, p < .01
25.30 ± 18.31*,†
18.35 ± 10.43‡
16.12 ± 10.09‡
F(2,134) = 4.48, p = .01
2.62 ± 1.63*
1.84 ± .91‡
2.11 ± 1.18

F(2,147) = 34.32, p < .001
t(49) = −2.60, p = .01, d = .37
t(49) = −11.64, p < .001, d = 1.66
t(49) = −10.13, p < .001, d = 1.43
F(2,134) = −0.88, p = .42
t(43) = 1.58, p = .12
t(46) = 2.41, p = .02, d = .35
t(45) = 0.78, p = .44
F(2,134) = 10.58, p < .001
t(43) = 1.37, p = .18
t(46) = 7.08, p < .001, d = 1.04
t(45) = 6.12, p < .001, d = .91
F(2,134) = 7.65, p = .001
t(43) = −1.20, p = .24
t(46) = −5.96, p < .001, d = 1.14
t(45) = −6.09, p < .001, d = .95
F(2,134) = 3.53, p = .03
t(43) = −2.65, p = .01, d = .43
t(46) = −7.34, p < .001, d = 1.07
t(45) = −4.68, p < .001, d = .69

F(2,128) = 23.68, p < .001
13.44 ± 4.64*,†; 80.0%
8.12 ± 4.25‡; 25.6%
6.95 ± 5.26‡; 25.2%
F(2,134) = 4.52, p = .01
6 hr 13 m ± 84 m†
6 hr 10 m ± 74 m†
6 hr 53 m ± 72 m†,‡
F(2,134) = 12.58, p < .001
3.12 ± .50*,†; Fair
3.51±.51‡; Fair/Good
3.66±.55‡; Good
F(2,134) = 0.65, p = .52
21.65 ± 13.46
20.84 ± 14.07
18.61 ± 11.75
F(2,134) = 3.28, p = .04
2.56 ± 1.49*
1.95 ± .89‡
2.06 ± 1.18

F(2,128) = 18.60, p < .001
t(44) = −3.76, p < .001, d = .57
t(42) = −10.60, p < .001, d = 1.62
t(42) = −8.97, p < .001, d = 1.38
F(2,134) = −0.74, p = .48
t(43) = 3.01, p < .01, d = .45
t(46) = 4.28, p < .001, d = .63
t(45) = 3.91, p < .001, d = .58
F(2,134) = 15.41, p < .001
t(43) = 1.51, p = .14
t(46) = 7.52, p < .001, d = 1.09
t(45) = 8.86, p < .001, d = 1.31
F(2,134) = 2.72, p = .07
t(43) = −3.42, p < .01, d = .52
t(46) = 5.34, p < .001, d = .90
t(45) = 5.47, p < .001, d = .83
F(2,134) = 1.83, p = .16
t(43) = −3.46, p < .01, d = .53
t(46) = −5.80, p < .001, d = .87
t(45) = −4.90, p < .001, d = .73

F(2,134) = 11.34, p <. 001
46.03 ± 32.61*,†
30.28 ± 21.89‡
22.11 ± 15.32‡

F(2,134) = 3.24, p = .04
t(43) = −3.83, p < .001, d = .60
t(46) = −6.08, p < .001, d = .95
t(45) = −6.42, p < .001, d = 1.07

F(2,134) = 5.88, p < .01
48.02 ± 36.61†
35.75 ± 23.29
28.10 ± 21.39‡

F(2,134) = 2.00, p = .14
t(43) = −3.20, p < .01, d = .49
t(46) = −5.68, p < .001, d = .89
t(45) = −4.67, p < .001, d = .71

F(2,134) = 6.46, p < .01
76% ± 14%*,†
83% ± 13%‡
86% ± 14%‡

F(2,134) = 4.32, p = .02
t(43) = 2.13, p = .04, d = .36
t(46) = 6.31, p < .001, d = .93
t(45) = 4.97, p < .001, d = .78

F(2,134) = 5.56, p < .01
77% ± 15%†
81% ± 12%
86% ± 10%a

F(2,134) = 2.78, p = .07
t(43) = 3.72, p < .01, d = .66
t(46) = 7.33, p < .001, d = 1.12
t(45) = 5.99, p < .001, d = .89

All other sleep parameters collected using the consensus sleep diary. In the posttreatment and 6 month follow-up columns, results from one-way ANOVAs
comparing group means, with Bonferroni post hoc comparisons.
*Mean different from SRT group.
†
Mean different from CBTI group. In the Δ Pre- to posttreatment and Δ Pre- to 6 month follow-up columns, F-statistic represents results from the Treatment × Time
interaction in a 3 × 2 repeated measures ANOVA. t-statistics represent results from paired samples t-tests to examine simple effects within each treatment group.
‡
Mean different from the SHE group.

Sleep maintenance
Sleep maintenance issues, as captured by number of nighttime
awakenings, WASO, and SE%, followed similar patterns (Table 2).
A Treatment × Time interaction was observed for nighttime
awakenings, such that SRT participants reported large reductions
nighttime awakenings after completing treatment (MeanT2−T1:
−.74, d = 1.07), whereas CBTI participants reported medium–
large reductions (MeanT2−T1: −.60, d = .69). SHE reported only
small reductions (MeanT2−T1: −.31, d = .43). Group comparisons
showed that the SRT group reported fewer awakenings than
the SHE group, although neither group differed from the CBTI
group. A Treatment × Time interaction was also observed for
WASO (Table 2; Figure 2). Both the SRT (MeanT2−T1: −32.04 min,
d = 1.07) and CBTI (MeanT2−T1: −26.96 min, d = .95) groups
reported large reductions in WASO at posttreatment, whereas
the SHE group reported a moderate reduction (MeanT2−T1:
−15.80, d = .60). Concordantly, SE% improvements were large
for patients receiving SRT (MeanT2−T1: +15%, d = .93) and CBTI
(MeanT2−T1: +10%, d = .78), whereas SE% increases in the SHE
group (MeanT2−T1: +5%, d = .36) were more modest, F(2,134) = 4.32,
p = .02. Posttreatment SE% was higher in the SRT (83% ± 13%) and
CBTI (86% ± 14%) groups than the SHE group (76% ± 14%).
Although sleep maintenance improved across all treatment
conditions, the results at 6 month follow-up were more

positive in the SRT and CBTI groups. Reductions in nighttime
awakenings were large in the SRT (MeanT2−T1: −.64, d = .87) and
CBTI (MeanT2−T1: −.67, d = .73) groups, but moderate in the SHE
group (MeanT2−T1: −.37, d = .53). Even so, fewer awakenings were
reported by SRT patients than SHE patients. Results for 6 month
outcomes for WASO and SE% were nearly identical such that
large improvements in WASO and SE% were observed in SRT
(SE% MeanT2−T1: +13%, WASO MeanT2−T1: −26.58 min) and CBTI
(SE% MeanT2−T1: +11%, WASO MeanT2−T1: −20.97 min) patients,
whereas moderate improvements were observed in the SHE
group (SE% MeanT2−T1: +7%, WASO MeanT2−T1: −13.81 min).
Notably, only CBTI patients reported better WASO and SE% than
the SHE group, whereas SRT differed from neither of the other
two treatment conditions. Moreover, mean levels of WASO and
SE% in the CBTI group were in the normal range (<31 min for
WASO and >85% for SE%), whereas these parameters were in
the insomnia range for patients in the SRT and SHE groups.

Remission rates and comparative odds by treatment
Lastly, we examined insomnia remission per three different
operationalizations: (1) ISI ≤ 7, (2) SE% ≥ 85%, and (3) SOL and
WASO ≤ 30 min each. We first evaluated remission rates by
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ISI
SHE
SRT
CBTI
Total sleep time
SHE
SRT
CBTI
Sleep quality
SHE
SRT
CBTI
Sleep latency
SHE
SRT
CBTI
Nighttime
awakenings
SHE
SRT
CBTI
Wake after sleep
onset
SHE
SRT
CBTI
Sleep efficiency
SHE
SRT
CBTI

Posttreatment
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treatment for all three remission operationalizations (Table 3).
We then ran dummy-coded logistic regression (SHE as the
reference group) to compare remission odds for CBTI and SRT
with that of the SHE group. For ISI-based remission, both SRT
and CBTI outperformed SHE at posttreatment and 6 month
follow-up (Table 3). Although effect sizes appeared larger for
the CBTI patients, logistic regression models comparing SRT
and CBTI patients revealed no difference in remission odds at
posttreatment or 6 month follow-up for the ISI-based remission.
Remission analyses based on SE% and SOL and WASO
showed somewhat similar results to the ISI-based remission

7

findings such that both SRT and CBTI outperformed SHE.
However, these results also diverged from ISI-based remission
results as evidence suggested that CBTI outperformed SRT at
posttreatment and 6 month follow-up (see Table 3 for full results.
Per SE%-based remission, higher odds of remission for CBTI
patients than SRT patients was nonsignificant at posttreatment
(OR = 2.23, p = .06). And at 6 month follow-up, this association
was significant such that CBTI patients were over twice as likely
to be in remission than SRT patients based on SE% (OR = 2.46,
95% CI = 1.08–5.61). SOL/WASO-based insomnia remission
revealed a greater likelihood of remission for CBTI patients

Table 3. Remission rates and odds at posttreatment and 6 month follow-up by treatment condition
Remission rates and odds
Posttreatment

OR, 95% CI

6 month Follow-up

OR, 95% CI

ISI ≤ 7
SHE
SRT
CBTI

2/50; 4.0%
19/50; 38.0%
27/50; 54.0%

–
14.71, 3.20–67.62
28.17, 6.16–128.80

6/45; 13.3%
24/43; 55.8%
29/43; 67.8%

–
7.47, 2.60–21.44
13.28, 4.49–39.30

SRT vs CBTI

CBTI: 1.92, .86-4.25

SRT vs CBTI

CBTI: 1.78, .73–4.36

SHE
SRT
CBTI

14/46; 30.4%
25/48; 52.1%
34/48; 70.8%
SRT vs CBT

SE% ≥ 85%
–
2.48, 1.07–5.79
5.55, 2.29–13.44
CBTI: 2.23, .96-5.18

12/46; 26.1%
19/47; 40.4%
30/48; 62.5%
SRT vs CBTI

–
1.92, .80–4.630
4.72, 1.96–11.39
CBTI: 2.46, 1.08–5.61

SHE
SRT
CBTI

16/48; 33.3%
28/49; 57.1%
41/49; 83.7%
SRT vs CBTI

SOL and WASO ≤ 30 min
–
2.67, 1.17–6.08
10.25, 3.90–26.94
CBTI: 3.84, 1.49–9.89

13/47; 27.7%
23/49; 46.9%
29/48; 60.4%
SRT vs CBTI

–
2.31, .99–5.42
3.99, 1.69–9.45
CBTI: 1.73, .77–3.86

SE% = sleep efficiency; SOL = sleep latency; OR = odds ratio relative to the sleep education group; 95% CI = 95% confidence interval for the OR.
SRT vs CBTI represents results (OR and 95% CI) from logistic regression models comparing SRT (coded 0) and CBTI (coded 1).
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Figure 2. Treatment effects of CBTI, SRT, and SHE on global insomnia, sleep quality, sleep latency, and wake after sleep onset.
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at posttreatment compared with SRT patients (OR = 3.84, 95%
CI = 1.49–9.89), whereas remission odds between CBTI and SRT
patients did not differ at 6 month follow-up (OR = 1.73, 95%
CI = 0.77–3.86).

Discussion
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In a sample of 150 postmenopausal women, we evaluated
the efficacy of CBTI and SRT in comparison to SHE for
chronic insomnia related to menopause. Both CBTI and SRT
outperformed SHE and resulted in large reductions in insomnia
symptoms after treatment. Improvements in sleep latency,
sleep maintenance, and overall insomnia symptomatology were
sustained 6 months later, reflecting durable treatment effects.
Importantly, CBTI and SRT produced large improvements
in most sleep parameters, indicating that both treatment
options are appropriate for improving menopausal insomnia.
Evidence suggested that only CBTI produced better long-term
sleep maintenance outcomes than SHE control, whereas SRT
did not differ from control on sleep maintenance outcomes.
Furthermore, some remission metrics suggested that CBTI
is associated with greater likelihood of remission than SRT.
Taken together, these data suggest that CBTI may be a superior
treatment option for most postmenopausal women with
insomnia.
The primary complaint prior to treatment in our study
was the inability to maintain sleep, thus confirming sleep
maintenance difficulties as the cardinal feature of menopauserelated insomnia [29–33]. Furthermore, our findings are highly
consistent with the recent MsFLASH clinical trial showing
that telephone delivery of CBTI effectively treats insomnia
when compared with menopause education control in
perimenopausal and postmenopausal women with high selfreported insomnia symptoms [16]. Indeed, CBTI treatment
response effect sizes for improvements in ISI, SOL, WASO,
and SE% are highly similar between the present study and
those reported in the MsFLASH telemedicine CBTI trial [16].
When comparing our results with other MsFLASH trials for the
treatment of menopausal insomnia, CBTI and SRT treatment
effects in our study were 2–3 times larger than those produced
by HRT (estradiol), antidepressant medication (escitalopram,
venlafaxine), yoga, and exercise [34]. Taken together, these
recent studies support face-to-face and telemedicine CBTI
and SRT as efficacious and durable first-line treatments for
menopausal insomnia.
The present study also adds to the literature in several key
ways: This trial is the first to test CBTI efficacy in women with
DSM-5 chronic insomnia disorder that onset or was exacerbated
during or after the menopause transition as diagnosed by a
behavioral sleep medicine specialist. This criterion was to
ensure that the menopause transition triggered or worsened
insomnia in our patients, rather than to focus on insomnia
that preexisted menopause and simply persisted through the
transition without change. Additionally, the present study is
the first to demonstrate the superiority of CBTI for menopausal
insomnia to an insomnia-focused minimal treatment control
condition (i.e. SHE) that approximates a real-world comparator
as sleep hygiene is often the nonpharmacological treatment
as usual for insomnia. This finding confirms that menopauserelated insomnia is a serious medical complaint that requires

specialty intervention to treat adequately, and that simply
improving sleep hygiene for women with menopausal insomnia
has very little benefit by itself.
Our study is also the first to compare two nonpharmacological
insomnia-focused treatments for menopausal insomnia:
CBTI vs SRT. SRT originated as a standalone treatment and is
empirically supported as an effective behavioral intervention for
insomnia disorder [19]. As a component of CBTI, sleep restriction
is considered one of the more active components [19, 35, 36].
And, to the best of our best knowledge, these two treatments
have never been directly compared in an RCT, despite several
insomnia trials each for CBTI and SRT. But along these lines,
Epstein et al. compared SRT to SRT + stimulus control therapy
(SCT, goal is to reduce cues associated with arousal and sleep
incompatibility, see Bootzin and Perlis [37] for in-depth analysis
of SCT), which are both CBTI components but do not comprise
a full course of CBTI [36]. Patients receiving SRT showed large
improvements in insomnia symptoms at 3 and 12 months after
treatment, and gains were similar to those reported by patients
who received combined SRT + SCT. However, remission rates
were nearly twice as high in the SRT + SCT condition (43.9%)
than in the SRT condition (22.7%).
Our findings were rather similar to Epstein’s dismantling
results [36] such that CBTI and SRT produced large improvements
in most sleep parameters in the acute period after treatment and
6 months later. Along these lines, remission rates based on the
ISI did not differ between CBTI and SRT. However, remission rates
based on SOL + WASO and SE% suggested that patients receiving
CBTI may be more likely to remit than those receiving SRT; these
data are consistent with Epstein’s remission findings comparing
multicomponent insomnia treatment with SRT. Where our
study findings diverge, however, is in our demonstration that
multicomponent insomnia intervention—CBTI in our case—
produces more durable long-term effects on sleep maintenance
as evidenced by more efficient sleep, less time awake in the
middle of the night, and longer nightly sleep duration compared
to SRT. It is possible that the additional components in CBTI, by
providing a broader set of personalized tools to utilize following
treatment, allow patients to address future exacerbations of
insomnia on their own, thereby preventing relapse. Indeed, our
findings here are similar to Harvey’s deconstruction findings
that CBTI and behavioral therapy for insomnia produce similar
acute treatment effects, but that CBTI’s treatment gains are
more durable than those produced by behavioral interventions
alone [38]. We therefore propose that CBTI and SRT are both
highly effective and appropriate standalone treatments for
menopausal insomnia, but that CBTI may produce higher rates
of insomnia remission and better long-term outcomes. Yet, it is
also important to emphasize that SRT produced largely similar
treatment effects in 2 weeks as compared to 6 weeks for CBTI,
thus indicating SRT is an impressively effective acute insomnia
intervention.
These comparative results are somewhat inconsistent with
our a priori hypotheses, as we predicted long-term treatment
response to be substantially better for CBTI patients than SRT
patients. Despite SRT’s prior support as a standalone treatment
[19, 35, 36], we anticipated that the additional components of
CBTI (stimulus control, cognitive therapy, relaxation, and sleep
hygiene) would have substantial incremental value to treatment
and reinforce longer-term adaptive sleep behaviors when
compared with SRT. Naturally, it is therefore incumbent on us
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Limitations and future directions
The present study should be interpreted in light of certain
limitations. Our primary limitation concerns a lack of follow-up
assessments beyond 6 months after treatment. Longer-term
prospective data would improve our understanding of the
durability of these effects in postmenopausal women. However,
a recent study suggests that durability of CBTI is maintained
10 years after treatment [53]. Regarding generalizability, PSG
verification of WASO is not required for insomnia diagnosis
nor is it typically performed in clinical practice, which can
limit the generalizability of our results to a broader patient

population. Furthermore, our sample was recruited from the
Metro Detroit area and certain racial and ethnic groups were
either under- or completely unrepresented, such as individuals
identifying as Hispanic, Asian, or Middle Eastern, which may limit
generalizability. In addition, the three conditions had different
treatment delivery modalities and dosing (SHE = 6 weekly emails;
SRT = 2 in-person sessions and 3 phone calls over 2 weeks; CBTI = 6
weekly face-to-face sessions), which may have contributed to
differences in treatment effects. Related, posttreatment outcomes
for the CBTI and SHE treatments (i.e. 6 week treatment regimens)
were collected 6 weeks after pretreatment baseline, whereas SRT
(i.e. a 2-week treatment regimen) posttreatment outcomes were
collected 2 weeks after pretreatment baseline. It is unclear if and
how these differences in posttreatment data collection schedules
may have affected results. Even so, delaying the posttreatment
SRT collection until 6 weeks after baseline was decided against
as there would have then been a 4 week delay between treatment
completion and posttreatment evaluation. Finally, due to
examining seven outcomes at two different posttreatment time
points, the present study included multiple comparisons, which
increases risk for type II errors.

Conclusions
CBTI and SRT are both viable and highly efficacious treatment
options for postmenopausal women with insomnia. Patients
receiving CBTI have remission rates of 54%–84% and SRT patients
have remission rates of 38%–57%. Higher remission rates and
greater improvements in sleep maintenance suggest that CBTI
may be a superior treatment option for most women. Even so,
SRT requires fewer treatment sessions than CBTI and produces
similarly sized treatment effects as CBTI; therefore, SRT represents
an especially attractive treatment option for patients limited in
their ability to attend multiple weekly treatment sessions and
may thus be an appropriate first-line option for consideration
in the context of a stepped-care approach. Lastly, although SHE
is a common insomnia-focused treatment and may slightly
improve some aspects of sleep, our results roundly reject it as an
appropriate standalone treatment for menopausal insomnia.
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